Rocket Pharmaceuticals, Inc. (RCKT)
Nasdaq · Healthcare · Biotechnology
$2.61+1.95%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $287M
- 52-week range
- $2.50 – $5.45
- 52-week change
- −19.50%
- EPS (trailing)
- −$0.17
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$223M
- Diluted EPS
- −$2.01
- Free cash flow
- −$190M
From the company’s annual report on SEC EDGAR.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Headquarters: Cranbury, United States · 202 employees · rocketpharma.com